reports
LendingTree Inc: 1 director
A director at LendingTree Inc sold 564 shares at 52.540USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Atlassian Announces First Quarter Fiscal Year 2025 Results
TEAM, Anywhere/SAN FRANCISCO--(BUSINESS WIRE)-- Atlassian Corporation (NASDAQ: TEAM), a leading provider of team collaboration and productivity software, today announced financial results for its first quarter ended September 30, 2024. A shareholder letter was posted on Atlassian’s Work Life blog at and in the Investor Relations section of Atlassian’s website at . First Quarter Fiscal Year 2025 Earnings Results “Through the power of our R&D engine, we’re not just marketing AI, we’re shipping it. I’m thrilled our team was able to launch Rovo, our latest product built for the AI era, into gen...
Atlassian Announces Date for First Quarter of Fiscal Year 2025 Financi...
TEAM, Anywhere/SAN FRANCISCO--(BUSINESS WIRE)-- Atlassian Corporation (NASDAQ: TEAM), a leading provider of team collaboration and productivity software, today announced that it will release financial results for its first quarter of fiscal year 2025 ended September 30, 2024 after market close on Thursday, October 31, 2024. Atlassian will host a conference call to discuss the financial results at 2:00 P.M. Pacific Time. In conjunction with its earnings press release, Atlassian will post a shareholder letter to the Investor Relations section of its website at . Webcast Details When: Thursday...
Atlassian Announces Fourth Quarter and Fiscal Year 2024 Results
Team Anywhere/SAN FRANCISCO--(BUSINESS WIRE)-- Atlassian Corporation (NASDAQ: TEAM), a leading provider of team collaboration and productivity software, today announced financial results for its fourth quarter and fiscal year 2024. A shareholder letter was posted on Atlassian’s Work Life blog at and in the Investor Relations section of Atlassian’s website at . Fourth Quarter Fiscal Year 2024 Earnings Results “This past year we’ve once again proved to ourselves that we can accomplish big things. We grew revenue to $4.4 billion, generated free cash flow of over $1.4 billion, and surged past...
Atlassian Appoints Scott Belsky, Adobe Chief Strategy Officer, to Boar...
Team Anywhere/SAN FRANCISCO--(BUSINESS WIRE)-- Atlassian Corporation (NASDAQ: TEAM), a leading provider of team collaboration and productivity software, today announced it is appointing Scott Belsky to its Board of Directors effective August 1, 2024. Scott is the Chief Strategy Officer and Executive Vice President, Design & Emerging Products, at Adobe (NASDAQ: ADBE), a leader in creative, digital document and digital experience technology. “I'm excited for Scott to bring his deep strategy and product experience to our Board. He's built loveable products used by millions of people around the ...
Atlassian Achieves FedRAMP “In Process” Designation
TEAM Anywhere/SAN FRANCISCO--(BUSINESS WIRE)-- Atlassian Corporation (NASDAQ: TEAM), a leading provider of team collaboration and productivity software, announced today that it has achieved Federal Risk and Authorization Management Program (FedRAMP) “In Process” status and is now listed on the . This important milestone brings Atlassian one step closer to achieving FedRAMP Moderate Authority to Operate (ATO) - which is currently estimated for the first quarter of calendar year 2025 - and is a significant part of Atlassian’s broader investment in supporting the U.S. public sector. The company...
Atlassian Announces Date for Fourth Quarter and Fiscal Year 2024 Finan...
TEAM, Anywhere/SAN FRANCISCO--(BUSINESS WIRE)-- Atlassian Corporation (NASDAQ: TEAM), a leading provider of team collaboration and productivity software, today announced that it will release financial results for its fourth quarter and fiscal year ended June 30, 2024 after market close on Thursday, August 1, 2024. Atlassian will host a webcast and conference call to discuss the financial results at 2:00 P.M. Pacific Time. In conjunction with its earnings press release, Atlassian will post a shareholder letter to the Investor Relations section of its website at . Webcast Details When: Thur...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PYPL PAYPAL HOLDINGS INC
LAKE LAKELAND INDUSTRIES INC.
ARMK ARAMARK
ARLP ALLIANCE RESOURCE PARTNERS L.P.
TREE LENDINGTREE INC.
UNFI UNITED NATURAL FOODS INC.
AEHR AEHR TEST SYSTEMS
HOV HOVNANIAN ENTERPRISES INC. CLASS A
PLMR PALOMAR HOLDINGS
AHCO ADAPTHEALTH
HOOD ROBINHOOD MARKETS INC
ASTS AST SPACEMOBILE INC
GTE GRAN TIERRA ENERGY INC.
SJM JM SMUCKER CO COM
QXO QXO INC COM
INSG INSEEGO CORP.
Moody's Ratings upgrades LendingTree's CFR to B3; outlook changed to s...
Moody's Ratings ("Moody's") upgraded LendingTree, Inc.'s ("LendingTree") corporate family rating (CFR) to B3 from Caa1. The B3 first lien senior secured credit facility rating and Caa1-PD probability of default rating (PDR) were both affirmed. The outlook was changed to stable from negative. The spe...
Atlassian Announces Third Quarter Fiscal Year 2024 Results and CEO Tra...
Team Anywhere/SAN FRANCISCO--(BUSINESS WIRE)-- Atlassian Corporation (NASDAQ: TEAM), a leading provider of team collaboration and productivity software, today announced financial results for its third quarter ended March 31, 2024. Atlassian also announced co-founder Scott Farquhar will step down as co-CEO effective August 31, 2024, with co-founder Mike Cannon Brookes continuing to lead Atlassian as CEO. A shareholder letter was posted on Atlassian’s Work Life blog at and in the Investor Relations section of Atlassian’s website at . Third Quarter Fiscal Year 2024 Earnings Results “It’s bee...
NGM Bio Announces Closing of Tender Offer
NGM Bio Announces Closing of Tender Offer SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an affiliate of The Column Group, LP (“TCG”), through its wholly-owned subsidiary Atlas Neon Merger Sub, Inc. (“Merger Sub”), has successfully completed the previously announced cash tender offer to acquire all outstanding shares of NGM Bio not held by affiliates of TCG and certain oth...
Atlassian Announces Dates for Third Quarter of Fiscal Year 2024 Financ...
Team Anywhere/SAN FRANCISCO--(BUSINESS WIRE)-- Atlassian Corporation (NASDAQ: TEAM), a leading provider of team collaboration and productivity software, today announced that it will release financial results for its third quarter of fiscal year 2024 ended March 31, 2024 after market close on Thursday, April 25, 2024. Atlassian will host a webcast and conference call to discuss the financial results at 2:00 P.M. Pacific Time. In conjunction with its earnings press release, Atlassian will post a shareholder letter to the Investor Relations section of its website at . Webcast Details When: T...
Moody's says LendingTree's raise of private capital ahead of upcoming ...
Moody's Ratings ("Moody's") said LendingTree, Inc.'s (LendingTree or the Company, Caa1 negative) raise of a 7-year, $175 million first-lien term loan due 2031 (the financing) is a potential credit positive. Moody's expects the company to use the net proceeds, plus internal sources of liquidity (most...
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ong...
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have be...
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter...
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results --Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 2024-- --Announced ongoing toxicology activities intended to support initiation of a potential proof-of-concept study of NGM120, a GDF15/GFRAL antagonist, for the treatment of hyperemesis gravida...
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger wit...
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP NGM Bio stockholders to receive $1.55 per share in cash, an 80% premium over the closing share price on the last trading day prior to disclosure of receipt from The Column Group of a non-binding expression of interest in purchasing shares in a going-private transactionBased on a thorough exploration and review of strategic and financial alternatives, a Special Committee of independent and disinterested directors unanimously recommends the transaction SAN FRANCISCO, Feb. 26, 2...
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a corporate panel discussion on novel oncology targets at the Cowen 44th Annual Health Care Conference on Tuesday, March 5th, at 9:10 am ET. A live webcast of the presentation will be available under the Investors and M...
Atlassian Announces Second Quarter Fiscal Year 2024 Results
Team Anywhere/SAN FRANCISCO--(BUSINESS WIRE)-- Atlassian Corporation (NASDAQ: TEAM), a leading provider of team collaboration and productivity software, today announced financial results for its second quarter ended December 31, 2023 and released a shareholder letter available on Atlassian’s Work Life blog at . The shareholder letter was also posted to the Investor Relations section of Atlassian’s website at . “Q2 was full of incredible milestones as we recorded our first-ever $1 billion revenue quarter, Jira Software crossed $1 billion in Cloud ARR, and we surpassed 300,000 customers,” said...
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology ...
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Jean-Frédéric Viret, Ph.D., Chief Financial Officer, will participate in the B. Riley Securities 4th Annual Oncology Conference and will provide a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Thursd...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.